Nintedanib

(Ofev®)

Nintedanib

Drug updated on 11/13/2023

Dosage FormCapsule (oral: 100 mg, 150 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of idiopathic pulmonary fibrosis (IPF).
  • For the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
  • For the slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Product Monograph / Prescribing Information

Document TitleYearSource
Ofev (nintedanib) Prescribing Information.2022Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.2023International journal of molecular sciences.
A Systematic Review of the Prognostic Significance of the Body Mass Index in Idiopathic Pulmonary Fibrosis.2023Journal of clinical medicine.
Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis2022BMJ Journals
Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.2022Respiratory medicine
Pharmacological treatments for SSc-ILD: systematic review and critical appraisal of the evidence. 2021Autoimmunity Reviews
Nintedanib for treating progressive fibrosing interstitial lung diseases.2021NICE
Clinical report: nintedanib (Ofev) for chronic fibrosing interstitial lung diseases.2021CADTH
Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis.2021Chest Journal
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.2021BMC Pulmonary Medicine
An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.2021Arthritis Research & Therapy
The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.2021PLOS ONE
Nintedanib for treating progressive fibrosing interstitial lung diseases.2021NICE
Clinical report: nintedanib (Ofev) for chronic fibrosing interstitial lung diseases.2021CADTH
Systematic review and meta-analysis of pirfenidone, nintedanib, and pamrevlumab for the treatment of idiopathic pulmonary fibrosis. 2020Annals of Pharmacotherapy
Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis.2020Journal of Clinical Medicine
Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis.2019Journal of Drug Assessment
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials.2019BMC Cancer

Clinical Practice Guidelines